STAAR Surgical Company

The China turnaround is gaining momentum, with Q2 2026 net sales exceeding $90 million — more than doubling the $44.3 million from Q2 2025. Wedbush reiterated an Outperform rating and $40 price target, citing continued confidence in the China ICL demand rebound and strong commercial execution.

Despite improved headline numbers, concerns remain about the durability of China's recovery. Wedbush previously flagged that STAAR needs a 'sustainable rebound in China,' and geopolitical and macroeconomic pressures persist, raising questions about whether demand is structurally sound or driven by temporary affordability dynamics.

Canaccord Genuity raised its price target to $32 with a buy rating, and Wedbush maintains a $40 target with an Outperform rating. The stock beat Q1 EPS estimates by 100% ($0.10 vs. $0.05 expected) and revenue by over $14 million, pointing to significant upside from current trading levels.

The broader analyst community remains cautious, with 6 of 11 analysts issuing Hold ratings and 2 issuing Sell ratings. Wells Fargo assigned only an Equal Weight with a $25 target, and the consensus average target of ~$27.81 implies minimal upside from current prices, reflecting deep skepticism about the rally's staying power.

Management has publicly acknowledged ERP system challenges and committed to resolving them in Q3 2026. The company's three strategic pillars — revenue growth, profit expansion, and innovation acceleration — remain intact, and strong Q2 preliminary results suggest operations have not been materially disrupted.

STAAR Surgical's stock dropped 11.5% on July 17 following the release of preliminary sales figures, with a Seeking Alpha analysis arguing the market's punishment was justified due to a lack of transparency. The ERP implementation challenges add execution risk, and the stock's history of 28 moves greater than 5% in a single year underscores its high volatility profile.